One Millionth Procedure Completed Using LENSAR’s Cataract Laser Systems
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced robotic laser solutions for cataract treatment, has announced a significant milestone: over one million procedures have been performed using its technology. Nick Curtis, President and CEO of LENSAR, emphasized the company's commitment to providing innovative robotic laser solutions that enhance clinical efficiencies and outcomes while revolutionizing the patient and surgical experience.
LENSAR introduced its cataract laser LLS platform in 2012 and has since developed the ALLY System, designed for robotic, laser cataract surgery. The ALLY System uniquely combines robotic intelligence and precision with surgeon expertise to deliver advanced cataract procedures aimed at consistently improving clinical outcomes and patient experiences. LENSAR remains the only company focused on robotic laser cataract surgery and plans to continue optimizing premium laser cataract surgery to bring greater value to surgeons, their staff, and patients.
LENSAR, Inc. (Nasdaq: LNSR), un'azienda globale di tecnologia medica specializzata in soluzioni laser robotiche avanzate per il trattamento della cataratta, ha annunciato un traguardo significativo: oltre un milione di procedure sono state effettuate utilizzando la propria tecnologia. Nick Curtis, Presidente e CEO di LENSAR, ha sottolineato l'impegno dell'azienda nel fornire soluzioni laser robotiche innovative che migliorano l'efficienza clinica e i risultati, rivoluzionando al contempo l'esperienza dei pazienti e quella chirurgica.
LENSAR ha introdotto la sua piattaforma laser per cataratta LLS nel 2012 e da allora ha sviluppato il System ALLY, progettato per la chirurgia della cataratta con laser robotico. Il System ALLY combina in modo unico intelligenza e precisione robotiche con l'esperienza del chirurgo, offrendo procedure avanzate per la cataratta mirate a migliorare costantemente i risultati clinici e l'esperienza dei pazienti. LENSAR rimane l'unica azienda focalizzata sulla chirurgia della cataratta con laser robotico e prevede di continuare a ottimizzare la chirurgia premium per la cataratta al fine di fornire maggiore valore ai chirurghi, al loro personale e ai pazienti.
LENSAR, Inc. (Nasdaq: LNSR), una empresa global de tecnología médica especializada en soluciones avanzadas de láser robótico para el tratamiento de cataratas, ha anunciado un hito significativo: se han realizado más de un millón de procedimientos utilizando su tecnología. Nick Curtis, Presidente y CEO de LENSAR, enfatizó el compromiso de la empresa con el suministro de soluciones innovadoras de láser robótico que mejoran las eficiencias clínicas y los resultados, al mismo tiempo que revolucionan la experiencia del paciente y la quirúrgica.
LENSAR presentó su plataforma láser LLS para cataratas en 2012 y desde entonces ha desarrollado el Sistema ALLY, diseñado para la cirugía de cataratas con láser robótico. El Sistema ALLY combina de manera única la inteligencia robótica y la precisión con la experiencia del cirujano para ofrecer procedimientos avanzados de cataratas que buscan mejorar constantemente los resultados clínicos y la experiencia de los pacientes. LENSAR sigue siendo la única empresa centrada en la cirugía de cataratas con láser robótico y planea continuar optimizando la cirugía premium de cataratas para aportar mayor valor a los cirujanos, su personal y los pacientes.
LENSAR, Inc. (Nasdaq: LNSR)는 백내장 치료를 위한 고급 로봇 레이저 솔루션을 전문으로 하는 글로벌 의료 기술 회사로, 100만 건 이상의 수술이 자사 기술을 사용하여 수행되었음을 발표했습니다. LENSAR의 대통령이자 CEO인 Nick Curtis는 임상 효율성과 결과를 향상시키고 환자 및 수술 경험을 혁신하는 혁신적인 로봇 레이저 솔루션을 제공하겠다는 회사의 다짐을 강조했습니다.
LENSAR는 2012년에 백내장 레이저 LLS 플랫폼을 소개했으며, 이후 로봇 레이저 백내장 수술을 위해 설계된 ALLY 시스템을 개발했습니다. ALY 시스템은 로봇 지능과 정밀성을 외과 의사의 전문성과 독특하게 결합하여 임상 결과와 환자 경험을 일관되게 개선하기 위한 고급 백내장 수술을 제공합니다. LENSAR는 로봇 레이저 백내장 수술에 집중하는 유일한 회사로, 외과 의사와 그들의 직원, 그리고 환자에게 더 큰 가치를 제공하기 위해 프리미엄 레이저 백내장 수술을 계속 최적화할 계획입니다.
LENSAR, Inc. (Nasdaq: LNSR), une entreprise mondiale de technologie médicale spécialisée dans des solutions laser robotiques avancées pour le traitement de la cataracte, a annoncé une étape importante : plus d'un million de procédures ont été réalisées grâce à sa technologie. Nick Curtis, Président et CEO de LENSAR, a souligné l'engagement de l'entreprise à fournir des solutions laser robotiques innovantes qui améliorent l'efficacité clinique et les résultats tout en révolutionnant l'expérience des patients et la chirurgie.
LENSAR a présenté sa plateforme laser LLS pour la cataracte en 2012 et a depuis développé le Système ALLY, conçu pour la chirurgie de la cataracte au laser robotique. Le Système ALLY combine de manière unique l'intelligence robotique et la précision avec l'expertise des chirurgiens pour offrir des procédures avancées de cataracte visant à améliorer de manière constante les résultats cliniques et l'expérience des patients. LENSAR reste la seule entreprise axée sur la chirurgie de la cataracte au laser robotique et prévoit de continuer à optimiser la chirurgie premium de la cataracte pour offrir une plus grande valeur aux chirurgiens, à leur personnel et aux patients.
LENSAR, Inc. (Nasdaq: LNSR), ein globales Medizintechnologieunternehmen, das sich auf fortschrittliche robotergestützte Laser-Lösungen zur Behandlung von Katarakten spezialisiert hat, hat einen bedeutenden Meilenstein angekündigt: Über eine Million Eingriffe wurden mit seiner Technologie durchgeführt. Nick Curtis, Präsident und CEO von LENSAR, betonte das Engagement des Unternehmens, innovative robotergestützte Laser-Lösungen zu bieten, die klinische Effizienz und Ergebnisse verbessern und gleichzeitig das Patienten- und chirurgische Erlebnis revolutionieren.
LENSAR stellte 2012 seine Katarakt-Laser-LLS-Plattform vor und hat seitdem das ALLY-System entwickelt, das für die robotergestützte Kataraktchirurgie konzipiert ist. Das ALLY-System kombiniert auf einzigartige Weise robotische Intelligenz und Präzision mit der Expertise des Chirurgen, um fortschrittliche Kataraktverfahren anzubieten, die darauf abzielen, klinische Ergebnisse und das Patientenerlebnis konstant zu verbessern. LENSAR bleibt das einzige Unternehmen, das sich auf die robotergestützte Kataraktchirurgie konzentriert, und plant, die hochwertige Laser-Kataraktchirurgie weiter zu optimieren, um den Chirurgen, deren Mitarbeitern und den Patienten einen größeren Nutzen zu bringen.
- Milestone achievement of over one million procedures performed using LENSAR's technology
- Development of the ALLY System, combining robotic intelligence with surgeon expertise
- Unique position as the only company focused on robotic laser cataract surgery
- None.
Insights
The completion of one million procedures using LENSAR's cataract laser systems marks a significant milestone for the company. This achievement demonstrates strong market adoption and surgeon acceptance of LENSAR's technology in the competitive ophthalmology space.
The ALLY System, combining robotic intelligence with surgeon expertise, represents a key differentiator for LENSAR. As the only company focused solely on robotic laser cataract surgery, LENSAR has carved out a niche in the
However, investors should note that with a market cap of just
While this milestone is positive for brand recognition and validates LENSAR's technology, its impact on near-term financials is likely Investors should look for data on procedure growth rates and market share gains in upcoming earnings reports to gauge the company's momentum.
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology.
“We are proud to celebrate this significant milestone with our surgeon partners. Our mission is to bring innovative robotic laser solutions to cataract surgeons to help them improve clinical efficiencies and outcomes, while revolutionizing the patient and surgical experience,” said Nick Curtis, President and CEO of LENSAR. “The completion of our millionth procedure is a testament to our longstanding commitment to provide premium robotic technology that we believe enhances the user experience and addresses the needs of our surgeon partners and their patients. We see the achievement of this milestone as confirmation that cataract surgeons recognize the many benefits that our robotic laser systems provide.”
LENSAR introduced its cataract laser LLS platform in 2012 and has worked closely with surgeon partners to develop the ALLY System. ALLY is designed to empower surgeons to perform not just standard laser cataract surgery but robotic, laser cataract surgery. Only the ALLY System combines robotic intelligence and precision with surgeon experience and expertise to deliver the most advanced cataract procedures with the goal of consistently delivering improved clinical outcomes and patient experiences.
“LENSAR is the only company focused on robotic laser cataract surgery and we will continue to optimize premium laser cataract surgery with the primary objective of bringing even greater value to surgeons, their staff and the patients they serve,” said Nick Curtis.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY ® Robotic Cataract Laser System as a compact, highly ergonomic system utilizing an extremely fast dual-pulse laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expected product advancement and the ALLY System’s performance, market adoption and usage. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.
Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, the important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in the Company’s other filings with the SEC. All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts:
Thomas R. Staab, II, CFO
ir.contact@lensar.com
Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Trade Media:
Levi Hall
L Communications for LENSAR
levi@lcommunications@me.com
Source: LENSAR, Inc.
FAQ
How many procedures have been performed using LENSAR's cataract laser systems?
What is the ALLY System developed by LENSAR (LNSR)?
When did LENSAR (LNSR) introduce its first cataract laser platform?
What makes LENSAR (LNSR) unique in the cataract surgery technology market?
